Analysis of Luohua Anshen oral Liquid combined with Ciying minimally invasive acupuncture in the treatment of comorbidized insomnia and sleep apnea:a randomized double-blind placebo-controlled study

注册号:

Registration number:

ITMCTR2025000742

最近更新日期:

Date of Last Refreshed on:

2025-04-14

注册时间:

Date of Registration:

2025-04-14

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

落花安神口服液联合刺营微创针刺治疗共病失眠与睡眠呼吸暂停的随机、双盲、安慰剂对照临床试验

Public title:

Analysis of Luohua Anshen oral Liquid combined with Ciying minimally invasive acupuncture in the treatment of comorbidized insomnia and sleep apnea:a randomized double-blind placebo-controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

落花安神口服液联合刺营微创针刺治疗共病失眠与睡眠呼吸暂停的随机、双盲、安慰剂对照临床试验

Scientific title:

Analysis of Luohua Anshen oral Liquid combined with Ciying minimally invasive acupuncture in the treatment of comorbidized insomnia and sleep apnea:a randomized double-blind placebo-controlled study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙艳君

研究负责人:

孙艳君

Applicant:

Sun Yanjun

Study leader:

Sun Yanjun

申请注册联系人电话:

Applicant telephone:

16622809395

研究负责人电话:

Study leader's telephone:

16622809395

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1915734861@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1915734861@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市静安区宝山路街道芷江中路274号上海市中医医院

研究负责人通讯地址:

上海市静安区宝山路街道芷江中路274号上海市中医医院

Applicant address:

Shanghai hospital of traditional Chinese medicine 274 Zhijiang Middle road Baoshan road Jing 'an district Shanghai

Study leader's address:

Shanghai hospital of traditional Chinese medicine 274 Zhijiang Middle road Baoshan road Jing 'an district Shanghai

申请注册联系人邮政编码:

Applicant postcode:

200040

研究负责人邮政编码:

Study leader's postcode:

200040

申请人所在单位:

上海市中医医院

Applicant's institution:

Shanghai Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025SHL-KY-61-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海市中医医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Hospital of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/3/28 0:00:00

伦理委员会联系人:

凌丽

Contact Name of the ethic committee:

Ling Li

伦理委员会联系地址:

上海市静安区宝山路街道芷江中路274号上海市中医医院

Contact Address of the ethic committee:

Shanghai hospital of traditional Chinese medicine 274 Zhijiang Middle road Baoshan road Jing 'an district Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

021-56628310

伦理委员会联系人邮箱:

Contact email of the ethic committee:

shszyyyec@126.com

研究实施负责(组长)单位:

上海市中医医院

Primary sponsor:

Shanghai Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市静安区宝山路街道芷江中路274号上海市中医医院

Primary sponsor's address:

Shanghai hospital of traditional Chinese medicine 274 Zhijiang Middle road Baoshan road Jing 'an district Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

静安区

Country:

China

Province:

Shanghai

City:

Shanghai

单位(医院):

上海市中医医院

具体地址:

上海市静安区宝山路街道芷江中路274号上海市中医医院

Institution
hospital:

Shanghai Hospital of Traditional Chinese Medicine

Address:

Shanghai hospital of traditional Chinese medicine 274 Zhijiang Middle road Baoshan road Jing 'an district Shanghai

经费或物资来源:

上海市卫生健康委员会

Source(s) of funding:

Shanghai Municipal Health Commission

研究疾病:

失眠共病阻塞性睡眠呼吸暂停

研究疾病代码:

Target disease:

Co-morbid insomnia and obstructive sleep apnea

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

探索落花安神口服液联合刺营微创针刺治疗共病失眠与睡眠呼吸暂停的疗效性和安全性,将针药结合治疗共病失眠合并睡眠呼吸暂停的新模式应用于临床实践,优化并完善现有失眠共病睡眠呼吸暂停中医药治疗的临床路径。

Objectives of Study:

To explore the efficacy and safety of Luohua Anshen oral liquid combined with Ciying minimally invasive acupuncture in the treatment of co-morbid insomnia and sleep apnea and apply the new mode into clinical practice and optimize and improve the existing clinical path of traditional Chinese medicine in the treatment of co-morbid insomnia and sleep apnea.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)同时符合上述阻塞性睡眠呼吸暂停综合征和失眠症的诊断标准; (2)年龄18~80岁; (3)未接受过OSA标准化治疗; (4)平素无服用安眠药,近2周未服用任何安眠类及精神类药物; (5)能独立配合完成各量表测评者; (6)自愿参加本研究并签署知情同意书,同意接受随访观察者。

Inclusion criteria

(1) Meet the above diagnostic criteria for obstructive sleep apnea syndrome and insomnia; (2) Age 18-80 years old; (3) Did not receive standardized OSA treatment; (4) No sleeping pills have been taken and no sleeping or psychotropic drugs have been taken in the past 2 weeks; (5) Those who can independently cooperate with each scale assessment; (6) Volunteer for participating in this study and sign informed consent and agree to accept follow-up observers.

排除标准:

(1)经检查有严重上气道解剖异常包括鼻中隔偏曲、鼻甲肥大、鼻息肉及鼻部肿瘤、Ⅱ度以上扁桃体肥大、咽腔狭窄、咽部肿瘤、咽腔黏膜肥厚、舌体肥大、舌根后坠、下颌后缩及小颌畸形者; (2)有呼吸道手术史和糖尿病患者; (3)筛选前长期服用影响中枢神经系统功能的精神类药物,如抗抑郁药、抗精神分裂症药和镇静催眠药等,且未在本实验筛选至少4周以前保持稳定服药剂量患者; (4)合并有心血管、肺、肝、肾、或造血系统、内分泌系统等严重疾病,精神疾患、脑器质性疾病及药物滥用或视力、听力明显障碍者; (5)妊娠或哺乳期妇女; (6)酗酒或药物依赖者; (7)存在精神、意识障碍且无法沟通交流者; (8)对本方案实验用药或所含成分过敏者; (9)正在参加其他药物临床试验,或在筛选前1个月参加过任何药物(排除维生素和矿物质)的临床试验者; (10)无法完成实验者或研究者认为其他原因不能入选者。

Exclusion criteria:

(1) Patients with severe upper airway anatomical abnormalities including nasal septum deviation turbinate hypertrophy nasal polyps and nasal tumors tonsil hypertrophy above degree Ⅱ pharyngeal stenosis pharyngeal tumor pharyngeal mucosa hypertrophy tongue hypertrophy posterior root of tongue fall mandibular retraction and micrognathia; (2) Patients with a history of respiratory surgery and diabetes; (3) Patients who have been taking psychotropic drugs that affect the function of the central nervous system for a long time before screening such as antidepressants anti-schizophrenia drugs sedative hypnotics etc. and have not maintained a stable dose of medication for at least 4 weeks before screening in this experiment; (4) Patients with serious diseases of cardiovascular lung liver kidney or hematopoietic system endocrine system mental disorders brain organic diseases drug abuse or visual and hearing impairment; (5) Pregnant or lactating women; (6) alcoholics or drug addicts; (7) Those who have mental and consciousness disorders and are unable to communicate; (8) Patients who are allergic to the experimental drug or the ingredients contained in this protocol; (9) Participants who are participating in clinical trials of other drugs or who have participated in clinical trials of any drug (excluding vitamins and minerals) in the month prior to screening; (10) Unable to complete for other reasons considered by the experimenter or researcher.

研究实施时间:

Study execute time:

From 2024-10-01

To      2027-09-30

征募观察对象时间:

Recruiting time:

From 2025-05-01

To      2027-09-30

干预措施:

Interventions:

组别:

对照组

样本量:

33

Group:

Control group

Sample size:

干预措施:

安慰剂联合刺营微创针刺治疗

干预措施代码:

Intervention:

Placebo combined with Ciying minimally invasive acupuncture treatment

Intervention code:

组别:

试验组

样本量:

33

Group:

Experimental group

Sample size:

干预措施:

落花安神口服液联合刺营微创针刺治疗

干预措施代码:

Intervention:

Luohua Anshen oral liquid combined with Ciying minimally invasive acupuncture treatment

Intervention code:

样本总量 Total sample size : 66

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海市

市(区县):

静安区

Country:

China

Province:

Shanghai

City:

Shanghai

单位(医院):

上海市中医医院

单位级别:

三级甲等医院

Institution/hospital:

Shanghai Hospital of Traditional Chinese Medicine

Level of the institution:

Class III Class A hospital

测量指标:

Outcomes:

指标中文名:

夜间最低血氧饱和度

指标类型:

主要指标

Outcome:

Minimum oxygen saturation at night

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

失眠严重程度指数量表评分

指标类型:

次要指标

Outcome:

Scores of Insomnia Severity Index Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数量表评分

指标类型:

主要指标

Outcome:

Scores of Pittsburgh Sleep Quality Index Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼吸暂停低通气指数

指标类型:

主要指标

Outcome:

Apnea - hypopnea index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

艾普沃斯嗜睡量表评分

指标类型:

次要指标

Outcome:

Scores of Epworth Sleepiness Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医症候量表评分

指标类型:

次要指标

Outcome:

Scores of TCM symptom scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由专业人员利用统计软件软件编码产生随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Statistical software is used by professionals to generate tables of random numbers

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above